No abstract

No abstract

et al. Structured, intensive education maximising engagement, motivation and long-term change for children and young people with diabetes: a cluster randomised controlled trial with integral process and economic evaluation -the CASCADE study. Health Technol Assess 2014;18(20).Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch ® ) and Current Contents ® / Clinical Medicine. Health Technology AssessmentHTA/HTA TAR ISSN 1366-5278 (Print) ISSN 2046-4924 (Online) Five-year impact factor: 5.804Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index and is assessed for inclusion in the Database of Abstracts of Reviews of Effects.This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: www.hta.ac.uk/ This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 06/44/05. The contractual start date was in May 2008. The draft report began editorial review in January 2013 and was accepted for publication in June 2013. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers...

Most evaluations of new treatments use highly selected populations, making it difficult to decide whether they would work elsewhere. Systematic evaluation and reporting of applicability is required Randomised trials of health interventions generally describe outcomes among participants with little consideration of whether the effects can be generalised. However, generalisability cannot be assumed with either biomedical interventions or more complex social interventions.w1 If their results are to be translatable into policy and practice decisions, trials must provide evidence about how relevant the interventions might be to other sites and populations.1 w2 Such information is particularly crucial for resource poor settings. 2Although CONSORT criteria for reporting randomised trials include assessment of generalisability, 3 a framework for empirically assessing and reporting this is lacking. We consider the factors affecting generalisability using examples from HIV and sexual health, examine how a sample of trials looked at generalisability, and suggest how to improve evaluation.